Carlisle Mum gets earlier cancer treatment thanks to 'revolutionary' blood test
A mother-of-two from Carlisle says she has been given her life back after receiving targeted cancer treatment.
Rebeca Proctor, 41, from Carlisle, was diagnosed with stage 4 non-small-cell lung cancer in January.
She was able to begin treatment earlier thanks to a new NHS liquid biopsy blood test, which identified a specific genetic mutation.
Ms Proctor said: "When I found out I had stage 4 cancer it felt like I'd been punched in the gut, I was scared – I just thought about my children, and if I would get to see my little girl start nursery, and how I would explain my diagnosis to my children – it was just heart-breaking to think about.
"But the medication has given me my life back and my kids have got their mum back.
"I'm taking it day by day and for now the treatment is doing what it's meant to be doing and shrinking the tumour, and I've got my energy back.
"I know I'm not going to be cured but I've come to terms with my diagnosis and the pills are stopping my cancer cells from spreading – we'll keep fighting this and dealing with what's been thrown at us."
The liquid biopsy revealed she had an ALK genetic mutation, allowing her to start a targeted therapy, brigatinib.
A traditional tissue biopsy confirmed the result around 10 days later.
Ms Proctor is under the care of Dr Sally Hall, a consultant medical oncologist at the Northern Centre for Cancer Care in North Cumbria.
The new blood test, now available across the NHS in England, detects fragments of tumour DNA in the bloodstream.
It identifies genetic mutations that can guide personalised cancer treatment.
NHS England recently announced that up to 15,000 patients with suspected lung cancer could benefit from the test each year.
An NHS pilot found that lung cancer patients could start targeted treatment up to 16 days sooner using the liquid biopsy compared to standard tissue biopsies.
The pilot also showed that some patients were able to avoid unnecessary chemotherapy and its side effects, improving their quality of life.
Professor Peter Johnson, NHS national clinical director for cancer, said: "Liquid biopsies are leading us into a new era of personalised cancer care and it's fantastic that we are now able to expand the use of this revolutionary test on the NHS to help tailor treatment for thousands of patients across the country.
"Cutting-edge genomic testing is helping us deliver more targeted and kinder care for patients, enabling some to avoid more intensive treatments such as further chemotherapy, which can have a huge impact."
Professor Alastair Greystoke, co-clinical lead of the ctDNA pilot and honorary medical oncologist at Newcastle Hospitals, said: "This is the first ever national implementation of a 'liquid biopsy first' approach to the diagnosis and treatment of a cancer."
"Not only has it led to faster and more precise treatment for patients with lung cancer, but we have also been able to show that this is a cost-effective measure for the NHS and set up the framework to evaluate this in other cancers going forward."
Professor Dame Sue Hill, chief scientific officer for England, said: "This represents a real step-change in care for eligible lung and breast cancer patients on the NHS.
"The liquid biopsy testing enables genomic mutations in the fragments of cancer that enter the bloodstream of these patients to be detected.
"This testing is transforming care and helping clinicians match patients earlier, especially when cancer tissue may not be available, with potentially life-extending targeted therapies rapidly and with greater precision."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 hours ago
- Yahoo
Waste depot staff given free health checks as part of initiative in Colchester
STAFF at a waste and recycling depot in Colchester have received free health checks as part of a workplace wellbeing initiative. The checks were conducted at the Shrub End depot by the NHS on the Open Road SOS Bus using a SiSU machine. This initiative identified staff with possible undiagnosed hypertension and formed part of Colchester Council's week-long focus on the health and wellbeing of its staff. The SiSU machine measured not only blood pressure, but also heart rate, body composition, and body mass index. Enthusiastic depot employees hopped aboard the bus for their checks. Mike Watkins, one of the staff members, expressed his gratitude, saying: "It makes us feel valued. "I'm keen to find out about my blood pressure and learn what to do about it if it's not where it should be." Martyn Peck (Image: Suffolk and North East Essex ICB) Worker Darren Hammett added: "I haven't had my blood pressure checked in a while, so I've come along today to find out what it is." The initiative also received positive feedback from staff, including Kevin Cook, who recommended other large workplaces to adopt similar practices. He said: "It's important to look after your health." Similarly, Martyn Peck expressed his desire for reassurance about his health and praised the initiative for aiding the early detection of health problems. Dr. Hasan Chowhan, senior partner at Creffield Medical Group, outlined the significance of the initiative. He said: "High blood pressure is a silent killer. "Many people don't realise they have the condition until they have a heart attack or stroke. "The good news is that it's possible to get it under control. For some that may mean making a few lifestyle changes; others will need to take medications as well. "These simple steps could save your life. "They could also help save your quality of life as both strokes and heart attacks can leave people with long-term disabilities." The initiative was planned with the indispensable support of the NHS Suffolk and North East Essex Integrated Care Board. Nerinda Evans, director of strategic programmes at the care board, said: "We helped to put on this event because we saw it as a great opportunity to talk to people directly about the dangers of undiagnosed high blood pressure. "Prevention is the key thing here. We are actively trying to support people before they have a heart attack or stroke. "We hope everyone at Colchester Recycling Centre will tell their friends and family about the importance of checking your blood pressure to help spread this important message.' The Open Road SOS Bus, commissioned by Essex County Council, plays a vital role in delivering workplace health checks, acting as a key aspect of its services. Stacey Banner, welfare and volunteer manager for the bus, said: "Early detection is crucial in preventing serious health conditions. "We are dedicated to ensuring that all individuals have access to fundamental healthcare services." This event also provided information about the new urgent care dental service, offering NHS treatment in one to seven days for problems like toothache, infections, and broken fillings. John Spence, councillor responsible for children's services, adult social care, public health and integration at Essex County Council, said: "Healthy workforces are happy and competitive workforces. "By taking the stations directly to local people, we are making health checks accessible and helping residents, especially those in manual jobs, take control of their health." The council's proactive approach extends beyond health checks, offering mental health support and other wellbeing aids for staff. Julie Young, deputy leader of Colchester Council and councillor responsible for housing, said: "We're proud to support initiatives that put our staff's wellbeing first. "The health checks at the household waste and recycling depot are a simple but powerful reminder that prevention saves lives. "This is exactly the kind of proactive approach we want to see more of across our workplaces – making it easier for people to take control of their health and stay well." People wanting workplace health checks, mental health support, or other staff wellbeing support can contact:
Yahoo
a day ago
- Yahoo
Weight loss pill set to rival injections after promising studies
A new daily weight loss pill has shown promising results in initial studies. Researchers say amycretin, which can be offered by injection or tablet, helped patients lose a significant amount of weight in the first trials. Those who received higher doses of amycretin as a weekly jab lost 24.3 per cent of their body weight after 36 weeks of treatment, while patients who took daily tablets lost an average of 13.1 per cent of their body weight after 12 weeks. While weight loss jabs have been hailed as transformative by NHS leaders, injections come with additional work for over-stretched health services, so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3 per cent after 36 weeks of treatment. It also showed signs of improving blood sugar levels. Side effects included nausea and vomiting, and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1 per cent of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7 per cent, with a third of participants losing 25 per cent or more of their body weight after 72 weeks.
Yahoo
a day ago
- Yahoo
Weight loss pill shows promise in new trial
A new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight, studies suggest. An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.
